Experts give an overview of the ASCO 2024 data.
Video content above is prompted by the following question:
The phase 2 CORE-001 trial investigated a new treatment combination of intravesical cretostimogene grenadenorepvec with pembrolizumab in patients with BCG-unresponsive, high-risk NMIBC. Before we review the trial background and results presented at the ASCO 2024 Annual Meeting, can you introduce cretostimogene and describe its mechanism of action?
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.